nach oben

Reviews in Endocrine and Metabolic Disorders

Erschienen in:

11.01.2018

Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature

verfasst von: Silvia Fabiani, Poupak Fallahi, Silvia Martina Ferrari, Mario Miccoli, Alessandro Antonelli

Erschienen in: Reviews in Endocrine and Metabolic Disorders | Ausgabe 4/2018

Einloggen, um Zugang zu erhalten

Abstract

Type 2 diabetes mellitus (T2DM) is an endocrine disorder encompassing multifactorial mechanisms, and chronic hepatitis C virus infection (CHC) is a multifaceted disorder, associated with extrahepatic manifestations, including endocrinological disorders. CHC and T2DM are associated, but the subject remains controversial. We performed a systematic review and meta-analysis evaluating such association, searching on PubMed until February 29, 2016. Inclusion criteria were: 1) presence of at least one internal control group age- and gender-matched (non-hepatopathic controls; and/or hepatopathic, not HCV-positive, controls); 2) sufficient data to calculate odds ratio and relative risk. Exclusion criteria were: 1) literature reviews on the topic; 2) publications regarding special populations [human immunodeficiency virus and human T-lymphotropic virus-1 coinfections, hepatocellular carcinoma (HCC), post-transplantation DM, gender selection]; 3) no clear differentiation among HCV patients with CHC, cirrhosis or HCC. Data from each study were independently extracted by two reviewers and cross-checked by AA. Our systematic review returned 544 records, and 33 were included in our meta-analysis. HCV infection is associated with an increased risk of T2DM independently from the severity of the associated liver disease, in CHC and cirrhotic HCV patients. As expected T2DM risk is higher in cirrhotic HCV patients, than CHC, and the prevalence of HCV infection in T2DM patients is higher than in non-diabetic controls. Regarding HBV infection prevalence, no difference exists in diabetic and non-diabetic subjects. An unequivocal CHC and T2DM association was shown. A proactive, integrated approach to HCV and T2DM therapies should maximize benefits of both diseases treatment.

Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345(1):41–52. https://doi.org/10.1056/NEJM200107053450107.CrossRef

Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature. 2001;414(6865):782–7. https://doi.org/10.1038/414782a.CrossRefPubMed

International Diabetes Federation Sixth Edition (2014). Available: http://www.idf.org/diabetesatlas.

Ferrannini E, Mari A. β-cell function in type 2 diabetes. Metabolism. 2014;63(10):1217–27. https://doi.org/10.1016/j.metabol.2014.05.012.CrossRefPubMed

Kahn SE, Cooper ME, Del Prato S. Pathophysiology and treatment of type 2 diabetes: Perspective on the past, present and future. Lancet. 2014;383(9922):1068–83. https://doi.org/10.1016/S0140-6736(13)62154-6.CrossRefPubMed

East HE, Subauste JS, Gandhi A, Koch CA. About secondary causes of diabetes mellitus. J Miss State Med Assoc. 2012;53(11):380–3.PubMed

Nati M, Haddad D, Birkenfeld AL, Koch CA, Chavakis T, Chatzigeorgiou A. The role of immune cells in metabolism-related liver inflammation and development of non-alcoholic steatohepatitis (NASH). Rev Endocr Metab Disord. 2016;17(1):29–39. https://doi.org/10.1007/s11154-016-9339-2.CrossRefPubMed

Koch CA, Bornstein SR, Birkenfeld AL. Introduction to Hanefeld symposium: 40+ years of metabolic syndrome. Rev Endocr Metab Disord. 2016;17(1):1–4. https://doi.org/10.1007/s11154-016-9356-1.CrossRefPubMed

Negro F, Forton D, Craxì A, Sulkowski MS, Feld JJ, Manns MP. Extrahepatic morbidity and mortality of chronic hepatitis C. Gastroenterology. 2015;149(6):1345–60. https://doi.org/10.1053/j.gastro.2015.08.035.CrossRefPubMed

10.

Fallahi P, Ferrari SM, Vita R, Benvenga S, Antonelli A. The role of human parvovirus B19 and hepatitis C virus in the development of thyroid disorders. Rev Endocr Metab Disord. 2016;17(4):529–35. https://doi.org/10.1007/s11154-016-9361-4.CrossRefPubMed

11.

Benvenga S, Guarneri F. Molecular mimicry and autoimmune thyroid disease. Rev Endocr Metab Disord. 2016;17(4):485–98. https://doi.org/10.1007/s11154-016-9363-2.CrossRefPubMed

12.

Alexander GJ. An association between hepatitis C virus infection and type 2 diabetes mellitus: What is the connection? Ann Intern Med. 2000;133(8):650–2. https://doi.org/10.7326/0003-4819-133-8-200010170-00018.CrossRefPubMed

13.

Mehta SH, Strathdee SA, Thomas DL. Association between hepatitis C virus infection and diabetes mellitus. Epidemiol Rev. 2001;23(2):302–12. https://doi.org/10.1093/oxfordjournals.epirev.a000808.CrossRefPubMed

14.

Mayo MJ. Extrahepatic manifestations of hepatitis C infection. Am J Med Sci. 2003;325(3):135–48. https://doi.org/10.1097/00000441-200303000-00006.CrossRefPubMed

15.

Lecube A, Hernández C, Genescà J, Simó R. Glucose abnormalities in patients with hepatitis C virus infection: Epidemiology and pathogenesis. Diabetes Care. 2006;29(5):1140–9. https://doi.org/10.2337/dc05-1995.CrossRefPubMed

16.

Noto H, Raskin P. Hepatitis C infection and diabetes. J Diabetes Complicat. 2006;20(2):113–20. https://doi.org/10.1016/j.jdiacomp.2006.01.001.CrossRefPubMed

17.

White DL, Ratziu V, El-Serag HB. Hepatitis C infection and risk of diabetes: A systematic review and meta-analysis. J Hepatol. 2008;49(5):831–44. https://doi.org/10.1016/j.jhep.2008.08.006.CrossRefPubMedPubMedCentral

18.

Bernsmeier C, Heim MH. Insulin resistance in chronic hepatitis C: Mechanisms and clinical relevance. Swiss Med Wkly. 2009;139(47-48):678–84.PubMed

19.

Negro F, Alaei M. Hepatitis C virus and type 2 diabetes. World J Gastroenterol. 2009;15(13):1537–47. https://doi.org/10.3748/wjg.15.1537.CrossRefPubMedPubMedCentral

20.

Naing C, Mak JW, Ahmed SI, Maung M. Relationship between hepatitis C virus infection and type 2 diabetes mellitus: Meta-analysis. World J Gastroenterol. 2012;18(14):1642–51. https://doi.org/10.3748/wjg.v18.i14.1642.CrossRefPubMedPubMedCentral

21.

Ruhl CE, Menke A, Cowie CC, Everhart JE. Relationship of hepatitis C virus infection with diabetes in the U.S. population. Hepatology. 2014;60(4):1139–49. https://doi.org/10.1002/hep.27047.CrossRefPubMedPubMedCentral

22.

Antonelli A, Ferrari SM, Giuggioli D, Di Domenicantonio A, Ruffilli I, Corrado A, et al. Hepatitis C virus infection and type 1 and type 2 diabetes mellitus. World J Diabetes. 2014;5(5):586–600. https://doi.org/10.4239/wjd.v5.i5.586.CrossRefPubMedPubMedCentral

23.

Prummel MF, Laurberg P. Interferon-alpha and autoimmune thyroid disease. Thyroid. 2003;13(6):547–51. https://doi.org/10.1089/105072503322238809.CrossRefPubMed

24.

Antonelli A, Ferri C, Fallahi P, Ferrari SM, Ghinoi A, Rotondi M, et al. Thyroid disorders in chronic hepatitis C virus infection. Thyroid. 2006;16(6):563–72. https://doi.org/10.1089/thy.2006.16.563.CrossRefPubMed

25.

Ozyilkan E, Arslan M. Increased prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Am J Gastroenterol. 1996;91(7):1480–1.PubMed

26.

Mangia A, Schiavone G, Lezzi G, Marmo R, Bruno F, Villani MR, et al. HCV and diabetes mellitus: Evidence for a negative association. Am J Gastroenterol. 1998;93(12):2363–7. https://doi.org/10.1111/j.1572-0241.1998.00688.x.CrossRefPubMed

27.

Knobler H, Schihmanter R, Zifroni A, Fenakel G, Schattner A. Increased risk of type 2 diabetes in noncirrhotic patients with chronic hepatitis C virus infection. Mayo Clin Proc. 2000;75(4):355–9. https://doi.org/10.4065/75.4.355.CrossRefPubMed

28.

Antonelli A, Ferri C, Fallahi P, Sebastiani M, Nesti C, Barani L, et al. Type 2 diabetes in hepatitis C-related mixed cryoglobulinaemia patients. Rheumatology (Oxford). 2004;43(2):238–40. https://doi.org/10.1093/rheumatology/keh011.CrossRef

29.

Antonelli A, Ferri C, Fallahi P, Pampana A, Ferrari SM, Goglia F, et al. Hepatitis C virus infection: Evidence for an association with type 2 diabetes. Diabetes Care. 2005;28(10):2548–50. https://doi.org/10.2337/diacare.28.10.2548.CrossRefPubMed

30.

Grimbert S, Valensi P, Lévy-Marchal C, Perret G, Richardet JP, Raffoux C, et al. High prevalence of diabetes mellitus in patients with chronic hepatitis C. A case–control study. Gastroenterol Clin Biol. 1996;20(6-7):544–8.PubMed

31.

Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J, et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;30(4):1059–63. https://doi.org/10.1002/hep.510300416.CrossRefPubMed

32.

Labropoulou-Karatza C, Goritsas C, Fragopanagou H, Repandi M, Matsouka P, Alexandrides T. High prevalence of diabetes mellitus among adult beta-thalassaemic patients with chronic hepatitis C. Eur J Gastroenterol Hepatol. 1999;11(9):1033–6. https://doi.org/10.1097/00042737-199909000-00014.CrossRefPubMed

33.

Mason AL, Lau JY, Hoang N, Qian K, Alexander GJ, Xu L, et al. Association of diabetes mellitus and chronic hepatitis C virus infection. Hepatology. 1999;29(2):328–33. https://doi.org/10.1002/hep.510290235.CrossRefPubMed

34.

Ryu JK, Lee SB, Hong SJ, Lee S. Association of chronic hepatitis C virus infection and diabetes mellitus in Korean patients. Korean J Intern Med. 2001;16(1):18–23. https://doi.org/10.3904/kjim.2001.16.1.18.CrossRefPubMedPubMedCentral

35.

Arao M, Murase K, Kusakabe A, Yoshioka K, Fukuzawa Y, Ishikawa T, et al. Prevalence of diabetes mellitus in Japanese patients infected chronically with hepatitis C virus. J Gastroenterol. 2003;38(4):355–60. https://doi.org/10.1007/s005350300063.CrossRefPubMed

36.

Lecube A, Hernández C, Genescà J, Esteban JI, Jardí R, Simó R. High prevalence of glucose abnormalities in patients with hepatitis C virus infection: A multivariate analysis considering the liver injury. Diabetes Care. 2004;27(5):1171–5. https://doi.org/10.2337/diacare.27.5.1171.CrossRefPubMed

37.

Imazeki F, Yokosuka O, Fukai K, Kanda T, Kojima H, Saisho H. Prevalence of diabetes mellitus and insulin resistance in patients with chronic hepatitis C: Comparison with hepatitis B virus-infected and hepatitis C virus-cleared patients. Liver Int. 2008;28(3):355–62. https://doi.org/10.1111/j.1478-3231.2007.01630.x.CrossRefPubMed

38.

Rouabhia S, Malek R, Bounecer H, Dekaken A, Bendali Amor F, Sadelaoud M, et al. Prevalence of type 2 diabetes in Algerian patients with hepatitis C virus infection. World J Gastroenterol. 2010;16(27):3427–31. https://doi.org/10.3748/wjg.v16.i27.3427.CrossRefPubMedPubMedCentral

39.

Allison ME, Wreghitt T, Palmer CR, Alexander GJ. Evidence for a link between hepatitis C virus infection and diabetes mellitus in a cirrhotic population. J Hepatol. 1994;21(6):1135–9. https://doi.org/10.1016/S0168-8278(05)80631-2.CrossRefPubMed

40.

Guerreo Igea FJ, Garrido Serrano A, Lepe Jiménez JA, Palomo Gil S. High prevalence of diabetes mellitus in patients with chronic hepatitis C virus infection. Med Clin (Barc). 1998;111(17):676–7.

41.

Bigam DL, Pennington JJ, Carpentier A, Wanless IR, Hemming AW, Croxford R, et al. Hepatitis C-related cirrhosis: A predictor of diabetes after liver transplantation. Hepatology. 2000;32(1):87–90. https://doi.org/10.1053/jhep.2000.8270.CrossRefPubMed

42.

Zein NN, Abdulkarim AS, Wiesner RH, Egan KS, Persing DH. Prevalence of diabetes mellitus in patients with end-stage liver cirrhosis due to hepatitis C, alcohol, or cholestatic disease. J Hepatol. 2000;32(2):209–17. https://doi.org/10.1016/S0168-8278(00)80065-3.CrossRefPubMed

43.

Baid S, Cosimi AB, Farrel ML, Schoenfeld DA, Feng S, Chung RT, et al. Posttransplant diabetes mellitus in liver transplant recipients: Risk factors, temporal relationship with hepatitis C virus allograft hepatitis, and impact on mortality. Transplantation. 2001;72(6):1066–72. https://doi.org/10.1097/00007890-200109270-00015.CrossRefPubMed

44.

Garrido Serrano A, Guerrero Igea FJ, Lepe Jiménez JA, Palomo Gil S, Grilo Reina A. Hyperinsulinemia in cirrhotic patients infected with hepatitis C virus. Gastroenterol Hepatol. 2001;24(3):127–31. https://doi.org/10.1016/S0210-5705(01)70138-0.CrossRefPubMed

45.

Thuluvath PJ, John PR. Association between hepatitis C, diabetes mellitus, and race. A case-control study. Am J Gastroenterol. 2003;98(2):438–41. https://doi.org/10.1111/j.1572-0241.2003.07256.x.CrossRefPubMed

46.

Parolin MB, Zaina FE, Araújo MV, Kupka E, Coelho JC. Prevalence of new-onset diabetes mellitus in Brazilian liver transplant recipients: Association with HCV infection. Transplant Proc. 2004;36(9):2776–7. https://doi.org/10.1016/j.transproceed.2004.10.029.CrossRefPubMed

47.

Simó R, Hernández C, Genescà J, Jardí R, Mesa J. High prevalence of hepatitis C virus infection in diabetic patients. Diabetes Care. 1996;19(9):998–1000. https://doi.org/10.2337/diacare.19.9.998.CrossRefPubMed

48.

Rudoni S, Petit JM, Bour JB, Aho LS, Castaneda A, Vaillant G, et al. HCV infection and diabetes mellitus: Influence of the use of finger stick devices on nosocomial transmission. Diabetes Metab. 1999;25(6):502–5.PubMed

49.

Chen HF, Li CY, Chen P, See TT, Lee HY. Seroprevalence of hepatitis B and C in type 2 diabetic patients. J Chin Med Assoc. 2006;69(4):146–52. https://doi.org/10.1016/S1726-4901(09)70195-9.CrossRefPubMed

50.

Ocak S, Duran N, Kaya H, Emir I. Seroprevalence of hepatitis C in patients with type 2 diabetes mellitus and non-diabetic on haemodialysis. Int J Clin Pract. 2006;60(6):670–4. https://doi.org/10.1111/j.1368-5031.2006.00738.x.CrossRefPubMed

51.

Gulcan A, Gulcan E, Toker A, Bulut I, Akcan Y. Evaluation of risk factors and seroprevalence of hepatitis B and C in diabetic patients in Kutahya, Turkey. J Investig Med. 2008;56(6):858–63. https://doi.org/10.2310/JIM.0b013e3181788d28.CrossRefPubMed

52.

Nwokediuko SC, Oli JM, Hepatitis C. Virus infection in Nigerians with diabetes mellitus. Niger J Clin Pract. 2008;11(2):94–9.PubMed

53.

Sjöberg K, Widell A, Verbaan H. Prevalence of hepatitis C in Swedish diabetics is low and comparable to that in health care workers. Eur J Gastroenterol Hepatol. 2008;20(2):135–8. https://doi.org/10.1097/MEG.0b013e3282f476f5.CrossRefPubMed

54.

Kaabia N, Ben Jazia E, Slim I, Fodha I, Hachfi W, Gaha R, et al. Association of hepatitis C virus infection and diabetes in central Tunisia. World J Gastroenterol. 2009;15(22):2778–81. https://doi.org/10.3748/wjg.15.2778.CrossRefPubMedPubMedCentral

55.

Jadoon NA, Shahzad MA, Yaqoob R, Hussain M. Ali N Seroprevalence of hepatitis C in type 2 diabetes: Evidence for a positive association. Virol J. 2010;7(1):304. https://doi.org/10.1186/1743-422X-7-304.CrossRefPubMedPubMedCentral

56.

Chehadeh W, Kurien SS, Abdella N, Ben-Nakhi A, Al-Arouj M, Almuaili T, et al. Hepatitis C virus infection in a population with high incidence of type 2 diabetes: Impact on diabetes complications. J Infect Public Health. 2011;4(4):200–6. https://doi.org/10.1016/j.jiph.2011.05.004.CrossRefPubMed

57.

Korkmaz H, Kesli R, Onder Pamuk B, Ipekci SH, Terzi Y, Kebapcilar L. Assessment of evidence for positive association and seroprevalence of hepatitis B and C in diabetic patients in a developing country. J Investig Med. 2015;63(2):251–7. https://doi.org/10.1097/JIM.0000000000000126.CrossRefPubMed

58.

Younossi ZM, McCullough AJ. Metabolic syndrome, non-alcoholic fatty liver disease and hepatitis C virus: Impact on disease progression and treatment response. Liver Int. 2009;29:3–12. https://doi.org/10.1111/j.1478-3231.2008.01949.x.CrossRefPubMed

59.

Negro F. Facts and fictions of HCV and comorbidities: Steatosis, diabetes mellitus, and cardiovascular diseases. J Hepatol. 2014;61(Suppl 1):S69–78. https://doi.org/10.1016/j.jhep.2014.08.003.CrossRefPubMed

60.

Guo X, Jin M, Yang M, Liu K, Li JW. Type 2 diabetes mellitus and the risk of hepatitis C virus infection: A systematic review. Sci Rep. 2013;3(1):2981. https://doi.org/10.1038/srep02981.CrossRefPubMedPubMedCentral

61.

García-Compeán D, González-González JA, Lavalle-González FJ, González-Moreno EI, Villarreal-Pérez JZ, Maldonado-Garza HJ. Current concepts in diabetes mellitus and chronic liver disease: Clinical outcomes, hepatitis C virus association, and therapy. Dig Dis Sci. 2016;61(2):371–8. https://doi.org/10.1007/s10620-015-3907-2.CrossRefPubMed

62.

Fabrizi F, Lampertico P, Lunghi G, Mangano S, Aucella F, Martin P. Review article: Hepatitis C virus infection and type-2 diabetes mellitus in renal diseases and transplantation. Aliment Pharmacol Ther. 2005;21(6):623–32. https://doi.org/10.1111/j.1365-2036.2005.02389.x.CrossRefPubMed

63.

Knobler H, Stagnaro-Green A, Wallenstein S, Schwartz M, Roman SH. Higher incidence of diabetes in liver transplant recipients with hepatitis C. J Clin Gastroenterol. 1998;26(1):30–3. https://doi.org/10.1097/00004836-199801000-00009.CrossRefPubMed

64.

Boschi-Pinto C, Stuver S, Okayama A, Trichopoulos D, Orav EJ, Tsubouchi H, et al. A follow-up study of morbidity and mortality associated with hepatitis C virus infection and its interaction with human T lymphotropic virus type I in Miyazaki, Japan. J Infect Dis. 2000;181(1):35–41. https://doi.org/10.1086/315177.CrossRefPubMed

65.

Howard AA, Klein RS, Schoenbaum EE. Association of hepatitis C infection and antiretroviral use with diabetes mellitus in drug users. Clin Infect Dis. 2003;36(10):1318–23. https://doi.org/10.1086/374838.CrossRefPubMed

66.

Butt AA, Fultz SL, Kwoh CK, Kelley D, Skanderson M, Justice AC. Risk of diabetes in HIV infected veterans pre- and post-HAART and the role of HCV coinfection. Hepatology. 2004;40(1):115–9. https://doi.org/10.1002/hep.20289.CrossRefPubMed

67.

Delgado-Borrego A, Casson D, Schoenfeld D, Somsouk M, Terella A, Jordan SH, et al. Hepatitis C virus is independently associated with increased insulin resistance after liver transplantation. Transplantation. 2004;77(5):703–10. https://doi.org/10.1097/01.TP.0000114283.04840.3A.CrossRefPubMed

68.

Wilson C, Hepatitis C. Infection and type 2 diabetes in American-Indian women. Diabetes Care. 2004;27(9):2116–9. https://doi.org/10.2337/diacare.27.9.2116.CrossRefPubMed

69.

Brar I, Shuter J, Thomas A, Daniels E, Absalon J. Minorities and Women's task force of Terry Beirn community programs for clinical research on AIDS. A comparison of factors associated with prevalent diabetes mellitus among HIV-infected antiretroviral-naive individuals versus individuals in the National Health and nutritional examination survey cohort. J Acquir Immune Defic Syndr. 2007;45(1):66–71. https://doi.org/10.1097/QAI.0b013e318031d7e3.CrossRefPubMed

70.

Jain MK, Aragaki C, Fischbach L, Gibson S, Arora R, May L, et al. Hepatitis C is associated with type 2 diabetes mellitus in HIV-infected persons without traditional risk factors. HIV Med. 2007;8(8):491–7. https://doi.org/10.1111/j.1468-1293.2007.00499.x.CrossRefPubMed

71.

Ledergerber B, Furrer H, Rickenbach M, Lehmann R, Elzi L, Hirschel B, et al. Factors associated with the incidence of type 2 diabetes mellitus in HIV-infected participants in the Swiss HIV cohort study. Clin Infect Dis. 2007;45(1):111–9. https://doi.org/10.1086/518619.CrossRefPubMed

72.

Stapleton JT, Bennett K, Bosch RJ, Polgreen PM, Swindells S. Effect of antiretroviral therapy and hepatitis c co-infection on changes in lipid levels in HIV-infected patients 48 weeks after initiation of therapy. HIV Clin Trials. 2007;8(6):429–36. https://doi.org/10.1310/hct0806-429.CrossRefPubMed

73.

Taura N, Ichikawa T, Miyaaki H, Yatsuhashi H, Ishibashi H, Nakao K. Prevalence of type 2 diabetes mellitus in Japanese patients with hepatocellular carcinoma. Exp Ther Med. 2011;2(1):81–4. https://doi.org/10.3892/etm.2010.167.CrossRefPubMed

74.

Visnegarwala F, Chen L, Raghavan S, Tedaldi E. Prevalence of diabetes mellitus and dyslipidemia among antiretroviral naive patients co-infected with hepatitis C virus (HCV) and HIV-1 compared to patients without co-infection. J Inf Secur. 2005;50:331–7.

75.

Younossi Z, Stepanova M, Saab S, Trimble G, Mishra A, Henry L. The association of hepatitis C virus infection and post-liver transplant diabetes: Data from 17 000 HCV-infected transplant recipients. Aliment Pharmacol Ther. 2015;41(2):209–17. https://doi.org/10.1111/apt.13027.CrossRefPubMed

76.

El-Zayadi AR, Selim OE, Hamdy H, Dabbous H, Ahdy A, Moniem SA. Association of chronic hepatitis C infection and diabetes mellitus. Trop Gastroenterol. 1998;19:141–4.PubMed

77.

AlDosary AA, Ramji AS, Elliott TG, Sirrs SM, Thompson DM, Erb SR, et al. Post-liver transplantation diabetes mellitus: An association with hepatitis C. Liver transp. 2002;8:356–61.CrossRef

78.

Yildiz A, Tutuncu Y, Yazici H, Akkaya V, Kayakan SM, Sever MS, et al. Association between hepatitis C virus infection and development of post-transplantation diabetes mellitus in renal transplant recipients. Transplantation. 2002;74(8):1109–13. https://doi.org/10.1097/00007890-200210270-00009.CrossRefPubMed

79.

Huang JF, Dai CY, Hwang SJ, Ho CK, Hsiao PJ, Hsieh MY, et al. Hepatitis C viremia increases the association with type 2 diabetes mellitus in a hepatitis B and C endemic area: An epidemiological link with virological implication. Am J Gastroenterol. 2007;102(6):1237–43. https://doi.org/10.1111/j.1572-0241.2007.01181.x.CrossRefPubMed

80.

Wang CS, Wang ST, Yao WJ, Chang TT, Chou P, Hepatitis C. Virus infection and the development of type 2 diabetes in a community-based longitudinal study. Am J Epidemiol. 2007;166(2):196–203. https://doi.org/10.1093/aje/kwm061.CrossRefPubMed

81.

Schnier C, Wild S, Kurdi Z, Povey C, Goldberg DJ, Hutchinson SJ. Matched population-based study examining the risk of type 2 diabetes in people with and without diagnosed hepatitis C virus infection. J Viral Hepat. 2016;23(8):596–605. https://doi.org/10.1111/jvh.12520.CrossRefPubMed

82.

Brischetto R, Corno C, Amore MG, Leotta S, Pavone S, Bonsignore L, et al. Prevalence and significance of type-2 diabetes mellitus in chronic liver disease, correlated with hepatitis C virus. Ann Ital Med Int. 2003;18(1):31–6.PubMed

83.

Montenegro L, De Michina A, Misciagna G, Guerra V, Di Leo A. Virus C hepatitis and Type 2 diabetes: A cohort study in southern Italy. Am J Gastroenterol. 2013;108(7):1108–11. https://doi.org/10.1038/ajg.2013.90.CrossRefPubMed

84.

Amarapurkar DN, Patel ND. Increased prevalence of type II diabetes mellitus in hepatitis C virus infection in western India. Trop Gastroenterol. 2008;29(3):148–52.PubMed

85.

Elhawary EI, Mahmoud GF, El-Daly MA, Mekky FA, Esmat GG, Abdel-Hamid M. Association of HCV with diabetes mellitus: An Egyptian case-control study. Virol J. 2011;8(1):367. https://doi.org/10.1186/1743-422X-8-367.CrossRefPubMedPubMedCentral

86.

Ratziu V, Heurtier A, Bonyhay L, Poynard T, Giral P. Review article: An unexpected virus-host interaction--the hepatitis C virus-diabetes link. Aliment Pharmacol Ther. 2005;22(suppl 2):56–60. https://doi.org/10.1111/j.1365-2036.2005.02598.x.CrossRefPubMed

87.

Masini M, Campani D, Boggi U, Menicagli M, Funel N, Pollera M, et al. Hepatitis C virus infection and human pancreatic beta-cell dysfunction. Diabetes Care. 2005;28(4):940–1. https://doi.org/10.2337/diacare.28.4.940.CrossRefPubMed

88.

Fallahi P, Ferri C, Ferrari SM, Corrado A, Sansonno D, Antonelli A. Cytokines and HCV-related disorders. Clin Dev Immunol. 2012;2012:468107.CrossRef

89.

Kita Y, Mizukoshi E, Takamura T, Sakurai M, Takata Y, Arai K, et al. Impact of diabetes mellitus on prognosis of patients infected with hepatitis C virus. Metabolism. 2007;56(12):1682–8. https://doi.org/10.1016/j.metabol.2007.07.011.CrossRefPubMed

90.

Wang CS, Yao WJ, Chang TT, Wang ST, Chou P. The impact of type 2 diabetes on the development of hepatocellular carcinoma in different viral hepatitis statuses. Cancer Epidemiol Biomark Prev. 2009;18(7):2054–60. https://doi.org/10.1158/1055-9965.EPI-08-1131.CrossRef

91.

Alter MJ, Margolis HS, Krawczynski K, Judson FN, Mares A, Alexander WJ, et al. The natural history of community-acquired hepatitis C in the United States. The sentinel counties chronic non-a, non-B hepatitis study team. N Engl J Med. 1992;327(27):1899–905. https://doi.org/10.1056/NEJM199212313272702.CrossRefPubMed

92.

Colombo M, Kuo G, Choo QL, Donato MF, Del Ninno E, Tommasini MA, et al. Prevalence of antibodies to hepatitis C virus in Italian patients with hepatocellular carcinoma. Lancet. 1989;2(8670):1006–8.CrossRef

93.

Tsukuma H, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med. 1993;328(25):1797–801. https://doi.org/10.1056/NEJM199306243282501.CrossRefPubMed

94.

El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology. 2004;126(2):460–8. https://doi.org/10.1053/j.gastro.2003.10.065.CrossRefPubMed

95.

Gao C, Yao SK. Diabetes mellitus: A “true” independent risk factor for hepatocellular carcinoma? Hepatobiliary Pancreat Dis Int. 2009;8(5):465–73.PubMed

96.

Elgouhari HM, Zein CO, Hanouneh I, Feldstein AE, Zein NN. Diabetes mellitus is associated with impaired response to antiviral therapy in chronic hepatitis C infection. Dig Dis Sci. 2009;54(12):2699–705. https://doi.org/10.1007/s10620-008-0683-2.CrossRefPubMed

97.

Nasrollah L, Backstedt DW, Pedersen MR, Choi M, Seetharam AB. Tu1022 Diabetes and Hyperlipidemia Compromise Practical Effectiveness of Direct Acting Antiviral HCV Therapy in Minority Populations. Gastroenterology. 2015;148 Suppl 1:S–1087.

98.

Knobler H, Malnick S. Hepatitis C and insulin action: An intimate relationship. World J Hepatol. 2016;8(2):131–8. https://doi.org/10.4254/wjh.v8.i2.131.CrossRefPubMedPubMedCentral

99.

Premji R, Roopnarinesingh N, Qazi N, Nylen ES. New-onset diabetes mellitus with exposure to Ledipasvir and Sofosbuvir. J Investig Med High Impact Case Rep. 2015;3:2324709615623300.PubMedPubMedCentral

100.

Pattullo V, Heathcote J. Hepatitis C and diabetes: One treatment for two diseases? Liver Int. 2010;30(3):356–64. https://doi.org/10.1111/j.1478-3231.2009.02185.x.CrossRefPubMed

101.

Milner KL, Jenkins AB, Trenell M, Tid-Ang J, Samocha-Bonet D, Weltman M, et al. Eradicating hepatitis C virus ameliorates insulin resistance without change in adipose depots. J Viral Hepat. 2014;21(5):325–32. https://doi.org/10.1111/jvh.12143.CrossRefPubMed

102.

Kawaguchi T, Ide T, Taniguchi E, Hirano E, Itou M, Sumie S, et al. Clearance of HCV improves insulin resistance, beta-cell function, and hepatic expression of insulin receptor substrate 1 and 2. Am J Gastroenterol. 2007;102(3):570–6. https://doi.org/10.1111/j.1572-0241.2006.01038.x.CrossRefPubMed

103.

Tallón de Lara P, Himschoot T, Frossard JL, Negro F. Does telaprevir possess a direct antidiabetic effect? Liver Int. 2014;34(6):967–9. https://doi.org/10.1111/liv.12440.CrossRefPubMed

104.

Vanni E, Bugianesi E, Saracco G. Treatment of type 2 diabetes mellitus by viral eradication in chronic hepatitis C: Myth or reality? Dig Liver Dis. 2016;48(2):105–11. https://doi.org/10.1016/j.dld.2015.10.016.CrossRefPubMed

105.

Younossi Z, Park H, Henry L, Adeyemi A, Stepanova M. Extrahepatic manifestations of hepatitis C: A meta-analysis of prevalence, quality of life, and economic burden. Gastroenterology. 2016;150(7):1599–608. https://doi.org/10.1053/j.gastro.2016.02.039.CrossRefPubMed

Titel: Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature
verfasst von: Silvia Fabiani
Poupak Fallahi
Silvia Martina Ferrari
Mario Miccoli
Alessandro Antonelli
Publikationsdatum: 11.01.2018
Verlag: Springer US
Erschienen in: Reviews in Endocrine and Metabolic Disorders / Ausgabe 4/2018
Print ISSN: 1389-9155
Elektronische ISSN: 1573-2606
DOI: https://doi.org/10.1007/s11154-017-9440-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Hepatitis C virus infection and development of type 2 diabetes mellitus: Systematic review and meta-analysis of the literature

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2018

Primary hypophysitis and other autoimmune disorders of the sellar and suprasellar regions

Immunoendocrinology: When (neuro)endocrinology and immunology meet

Endocrine disorders associated with hepatitis C virus chronic infection

Innate immune cells in the adipose tissue

Statins, metformin, proprotein-convertase-subtilisin-kexin type-9 (PCSK9) inhibitors and sex hormones: Immunomodulatory properties?

Thyroid disorders induced by checkpoint inhibitors

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Update Innere Medizin